Review



cta protein array  (Sengenics Corporation Pte)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Sengenics Corporation Pte cta protein array
    Antigen reactivities identified with ovarian cancer cohort 1 using <t> Sengenics </t> <t> CTA protein </t> arrays. Ovarian cancer ASC probes ( n = 11, A–K) and selected matched sera ( n = 5) were screened using <t> Sengenics </t> <t> CTA protein </t> arrays.
    Cta Protein Array, supplied by Sengenics Corporation Pte, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cta+protein+array/cta+protein+array/pmc08538754-157-2-1
    Average 90 stars, based on 1 article reviews
    cta protein array - by Bioz Stars, 2026-11
    90/100 stars

    Images

    1) Product Images from "Identification of Tumor Antigens in Ovarian Cancers Using Local and Circulating Tumor-Specific Antibodies"

    Article Title: Identification of Tumor Antigens in Ovarian Cancers Using Local and Circulating Tumor-Specific Antibodies

    Journal: International Journal of Molecular Sciences

    doi: 10.3390/ijms222011220

    Antigen reactivities identified with ovarian cancer cohort 1 using Sengenics CTA protein arrays. Ovarian cancer ASC probes ( n = 11, A–K) and selected matched sera ( n = 5) were screened using Sengenics CTA protein arrays.
    Figure Legend Snippet: Antigen reactivities identified with ovarian cancer cohort 1 using Sengenics CTA protein arrays. Ovarian cancer ASC probes ( n = 11, A–K) and selected matched sera ( n = 5) were screened using Sengenics CTA protein arrays.

    Techniques Used:

    Study design diagram. Ovarian cancer cohort 1 and selected healthy and benign controls were screened using the CDI HuProt TM array and the Sengenics CTA protein array, which led to the identification of 50 candidate antigens. A custom array was developed and used to screen ovarian cancer cohort 2, as well as healthy and benign controls.
    Figure Legend Snippet: Study design diagram. Ovarian cancer cohort 1 and selected healthy and benign controls were screened using the CDI HuProt TM array and the Sengenics CTA protein array, which led to the identification of 50 candidate antigens. A custom array was developed and used to screen ovarian cancer cohort 2, as well as healthy and benign controls.

    Techniques Used: Protein Array

    Related Articles

    Clinical Proteomics:

    Article Title: Poster Presentations
    Article Snippet: International Journal of Rheumatic Diseases, 2025 around 43% of patients develop Raynaud's phenomenon (RP).. Its presentation may be confused with some autoimmune diseases, including lupus and therefore should be considered in the differential of patients with secondary RP.. Case Study: A previously well, white male in his twenties, was diagnosed with retinal vasculopathy following a routine eye check.

    Article Title: Novel IgG and IgA autoantibodies validated in two independent cohorts are associated with disease activity and determine organ manifestations in systemic lupus erythematosus: implications for anti-LIN28A, anti-HMGN5, anti-IRF5, and anti-TGIF1.
    Article Snippet: Plasma from patients with SLE in 2 independent cohorts was screened for IgG and IgA seroreactivity against 1609 protein autoantigens using the i-Ome Discovery microarray (Sengenics), with 3 longitudinal assessments conducted in the smaller validation cohort.

    Article Title: T cell and autoantibody profiling for primary immune regulatory disorders.
    Article Snippet: Background: Limited clinical tools exist for characterizing primary immune regulatory disorders (PIRD).. Increased CD4CXCR5PD1 circulating T follicular helper (cTfh) cell percentages have been identified as a marker of active disease in some, but not all, autoimmune disorders.. Objective: To develop a diagnostic approach that combines measurements of cellular and serologic autoimmunity.

    Article Title: Advances in Extracellular Matrix-Associated Diagnostics and Therapeutics.
    Article Snippet: 2025, 14, 1856 31 of 50 biomarker discovery and introduced Sengenics’ revolutionary KREX® protein microarray technology.

    Article Title: New IgG and IgA autoantibody specificities against DNA-binding and RNA-binding proteins discriminate systemic lupus erythematosus from health and non-lupus autoimmunity-could anti-LIN28A enhance precision in diagnostics?
    Article Snippet: While most SLE autoantibody studies focus on the IgG isotype, including the 2 previous studies that used the Sengenics i-Ome microarray, our study also examined IgA autoantibodies.

    Article Title: Novel IgG and IgA autoantibodies validated in two independent cohorts are associated with disease activity and determine organ manifestations in systemic lupus erythematosus: implications for anti-LIN28A, anti-HMGN5, anti-IRF5, and anti-TGIF1.
    Article Snippet: Autoantibody measurement and gene expression analysis Plasma samples were screened for IgG and IgA autoantibody specificities against a panel of 1609 human proteins using the i-Ome Discovery protein microarray (Sengenics Corporation; Supplementary Material, sheet 1) [23].

    Article Title: New IgG and IgA autoantibody specificities against DNA-binding and RNA-binding proteins discriminate systemic lupus erythematosus from health and non-lupus autoimmunity-could anti-LIN28A enhance precision in diagnostics?
    Article Snippet: Two previous studies have used the Sengenics i-Ome highthroughput proteomic microarray to identify IgG autoantibodies in geographically distinct SLE populations from Singapore [25] and the UK [5].

    Article Title: Novel IgG and IgA autoantibodies validated in two independent cohorts are associated with disease activity and determine organ manifestations in systemic lupus erythematosus: implications for anti-LIN28A, anti-HMGN5, anti-IRF5, and anti-TGIF1.
    Article Snippet: To address this need, we aimed to uncover novel biomarkers that could enhance our ability to monitor SLE disease activity more accurately and tailor treatments more effectively using the i-Ome Discovery protein microarray (Sengenics Corporation) that encompasses 1609 protein autoantigens.

    Control:

    Article Title: Poster Presentations
    Article Snippet: International Journal of Rheumatic Diseases, 2025 around 43% of patients develop Raynaud's phenomenon (RP).. Its presentation may be confused with some autoimmune diseases, including lupus and therefore should be considered in the differential of patients with secondary RP.. Case Study: A previously well, white male in his twenties, was diagnosed with retinal vasculopathy following a routine eye check.

    Article Title: Novel IgG and IgA autoantibodies validated in two independent cohorts are associated with disease activity and determine organ manifestations in systemic lupus erythematosus: implications for anti-LIN28A, anti-HMGN5, anti-IRF5, and anti-TGIF1.
    Article Snippet: Plasma from patients with SLE in 2 independent cohorts was screened for IgG and IgA seroreactivity against 1609 protein autoantigens using the i-Ome Discovery microarray (Sengenics), with 3 longitudinal assessments conducted in the smaller validation cohort.

    Article Title: T cell and autoantibody profiling for primary immune regulatory disorders.
    Article Snippet: Background: Limited clinical tools exist for characterizing primary immune regulatory disorders (PIRD).. Increased CD4CXCR5PD1 circulating T follicular helper (cTfh) cell percentages have been identified as a marker of active disease in some, but not all, autoimmune disorders.. Objective: To develop a diagnostic approach that combines measurements of cellular and serologic autoimmunity.

    Article Title: Advances in Extracellular Matrix-Associated Diagnostics and Therapeutics.
    Article Snippet: 2025, 14, 1856 31 of 50 biomarker discovery and introduced Sengenics’ revolutionary KREX® protein microarray technology.

    Article Title: New IgG and IgA autoantibody specificities against DNA-binding and RNA-binding proteins discriminate systemic lupus erythematosus from health and non-lupus autoimmunity-could anti-LIN28A enhance precision in diagnostics?
    Article Snippet: While most SLE autoantibody studies focus on the IgG isotype, including the 2 previous studies that used the Sengenics i-Ome microarray, our study also examined IgA autoantibodies.

    Article Title: Novel IgG and IgA autoantibodies validated in two independent cohorts are associated with disease activity and determine organ manifestations in systemic lupus erythematosus: implications for anti-LIN28A, anti-HMGN5, anti-IRF5, and anti-TGIF1.
    Article Snippet: Autoantibody measurement and gene expression analysis Plasma samples were screened for IgG and IgA autoantibody specificities against a panel of 1609 human proteins using the i-Ome Discovery protein microarray (Sengenics Corporation; Supplementary Material, sheet 1) [23].

    Article Title: New IgG and IgA autoantibody specificities against DNA-binding and RNA-binding proteins discriminate systemic lupus erythematosus from health and non-lupus autoimmunity-could anti-LIN28A enhance precision in diagnostics?
    Article Snippet: Two previous studies have used the Sengenics i-Ome highthroughput proteomic microarray to identify IgG autoantibodies in geographically distinct SLE populations from Singapore [25] and the UK [5].

    Article Title: Novel IgG and IgA autoantibodies validated in two independent cohorts are associated with disease activity and determine organ manifestations in systemic lupus erythematosus: implications for anti-LIN28A, anti-HMGN5, anti-IRF5, and anti-TGIF1.
    Article Snippet: To address this need, we aimed to uncover novel biomarkers that could enhance our ability to monitor SLE disease activity more accurately and tailor treatments more effectively using the i-Ome Discovery protein microarray (Sengenics Corporation) that encompasses 1609 protein autoantigens.

    High Throughput Screening Assay:

    Article Title: Poster Presentations
    Article Snippet: International Journal of Rheumatic Diseases, 2025 around 43% of patients develop Raynaud's phenomenon (RP).. Its presentation may be confused with some autoimmune diseases, including lupus and therefore should be considered in the differential of patients with secondary RP.. Case Study: A previously well, white male in his twenties, was diagnosed with retinal vasculopathy following a routine eye check.

    Article Title: Novel IgG and IgA autoantibodies validated in two independent cohorts are associated with disease activity and determine organ manifestations in systemic lupus erythematosus: implications for anti-LIN28A, anti-HMGN5, anti-IRF5, and anti-TGIF1.
    Article Snippet: Plasma from patients with SLE in 2 independent cohorts was screened for IgG and IgA seroreactivity against 1609 protein autoantigens using the i-Ome Discovery microarray (Sengenics), with 3 longitudinal assessments conducted in the smaller validation cohort.

    Article Title: T cell and autoantibody profiling for primary immune regulatory disorders.
    Article Snippet: Background: Limited clinical tools exist for characterizing primary immune regulatory disorders (PIRD).. Increased CD4CXCR5PD1 circulating T follicular helper (cTfh) cell percentages have been identified as a marker of active disease in some, but not all, autoimmune disorders.. Objective: To develop a diagnostic approach that combines measurements of cellular and serologic autoimmunity.

    Article Title: Advances in Extracellular Matrix-Associated Diagnostics and Therapeutics.
    Article Snippet: 2025, 14, 1856 31 of 50 biomarker discovery and introduced Sengenics’ revolutionary KREX® protein microarray technology.

    Article Title: New IgG and IgA autoantibody specificities against DNA-binding and RNA-binding proteins discriminate systemic lupus erythematosus from health and non-lupus autoimmunity-could anti-LIN28A enhance precision in diagnostics?
    Article Snippet: While most SLE autoantibody studies focus on the IgG isotype, including the 2 previous studies that used the Sengenics i-Ome microarray, our study also examined IgA autoantibodies.

    Article Title: Novel IgG and IgA autoantibodies validated in two independent cohorts are associated with disease activity and determine organ manifestations in systemic lupus erythematosus: implications for anti-LIN28A, anti-HMGN5, anti-IRF5, and anti-TGIF1.
    Article Snippet: Autoantibody measurement and gene expression analysis Plasma samples were screened for IgG and IgA autoantibody specificities against a panel of 1609 human proteins using the i-Ome Discovery protein microarray (Sengenics Corporation; Supplementary Material, sheet 1) [23].

    Article Title: New IgG and IgA autoantibody specificities against DNA-binding and RNA-binding proteins discriminate systemic lupus erythematosus from health and non-lupus autoimmunity-could anti-LIN28A enhance precision in diagnostics?
    Article Snippet: Two previous studies have used the Sengenics i-Ome highthroughput proteomic microarray to identify IgG autoantibodies in geographically distinct SLE populations from Singapore [25] and the UK [5].

    Article Title: Novel IgG and IgA autoantibodies validated in two independent cohorts are associated with disease activity and determine organ manifestations in systemic lupus erythematosus: implications for anti-LIN28A, anti-HMGN5, anti-IRF5, and anti-TGIF1.
    Article Snippet: To address this need, we aimed to uncover novel biomarkers that could enhance our ability to monitor SLE disease activity more accurately and tailor treatments more effectively using the i-Ome Discovery protein microarray (Sengenics Corporation) that encompasses 1609 protein autoantigens.

    Microarray:

    Article Title: Poster Presentations
    Article Snippet: International Journal of Rheumatic Diseases, 2025 around 43% of patients develop Raynaud's phenomenon (RP).. Its presentation may be confused with some autoimmune diseases, including lupus and therefore should be considered in the differential of patients with secondary RP.. Case Study: A previously well, white male in his twenties, was diagnosed with retinal vasculopathy following a routine eye check.

    Article Title: Novel IgG and IgA autoantibodies validated in two independent cohorts are associated with disease activity and determine organ manifestations in systemic lupus erythematosus: implications for anti-LIN28A, anti-HMGN5, anti-IRF5, and anti-TGIF1.
    Article Snippet: Plasma from patients with SLE in 2 independent cohorts was screened for IgG and IgA seroreactivity against 1609 protein autoantigens using the i-Ome Discovery microarray (Sengenics), with 3 longitudinal assessments conducted in the smaller validation cohort.

    Article Title: T cell and autoantibody profiling for primary immune regulatory disorders.
    Article Snippet: Background: Limited clinical tools exist for characterizing primary immune regulatory disorders (PIRD).. Increased CD4CXCR5PD1 circulating T follicular helper (cTfh) cell percentages have been identified as a marker of active disease in some, but not all, autoimmune disorders.. Objective: To develop a diagnostic approach that combines measurements of cellular and serologic autoimmunity.

    Article Title: Advances in Extracellular Matrix-Associated Diagnostics and Therapeutics.
    Article Snippet: 2025, 14, 1856 31 of 50 biomarker discovery and introduced Sengenics’ revolutionary KREX® protein microarray technology.

    Article Title: New IgG and IgA autoantibody specificities against DNA-binding and RNA-binding proteins discriminate systemic lupus erythematosus from health and non-lupus autoimmunity-could anti-LIN28A enhance precision in diagnostics?
    Article Snippet: While most SLE autoantibody studies focus on the IgG isotype, including the 2 previous studies that used the Sengenics i-Ome microarray, our study also examined IgA autoantibodies.

    Article Title: Novel IgG and IgA autoantibodies validated in two independent cohorts are associated with disease activity and determine organ manifestations in systemic lupus erythematosus: implications for anti-LIN28A, anti-HMGN5, anti-IRF5, and anti-TGIF1.
    Article Snippet: Autoantibody measurement and gene expression analysis Plasma samples were screened for IgG and IgA autoantibody specificities against a panel of 1609 human proteins using the i-Ome Discovery protein microarray (Sengenics Corporation; Supplementary Material, sheet 1) [23].

    Article Title: New IgG and IgA autoantibody specificities against DNA-binding and RNA-binding proteins discriminate systemic lupus erythematosus from health and non-lupus autoimmunity-could anti-LIN28A enhance precision in diagnostics?
    Article Snippet: Two previous studies have used the Sengenics i-Ome highthroughput proteomic microarray to identify IgG autoantibodies in geographically distinct SLE populations from Singapore [25] and the UK [5].

    Article Title: Novel IgG and IgA autoantibodies validated in two independent cohorts are associated with disease activity and determine organ manifestations in systemic lupus erythematosus: implications for anti-LIN28A, anti-HMGN5, anti-IRF5, and anti-TGIF1.
    Article Snippet: To address this need, we aimed to uncover novel biomarkers that could enhance our ability to monitor SLE disease activity more accurately and tailor treatments more effectively using the i-Ome Discovery protein microarray (Sengenics Corporation) that encompasses 1609 protein autoantigens.

    Immunopeptidomics:

    Article Title: Poster Presentations
    Article Snippet: International Journal of Rheumatic Diseases, 2025 around 43% of patients develop Raynaud's phenomenon (RP).. Its presentation may be confused with some autoimmune diseases, including lupus and therefore should be considered in the differential of patients with secondary RP.. Case Study: A previously well, white male in his twenties, was diagnosed with retinal vasculopathy following a routine eye check.

    Article Title: Novel IgG and IgA autoantibodies validated in two independent cohorts are associated with disease activity and determine organ manifestations in systemic lupus erythematosus: implications for anti-LIN28A, anti-HMGN5, anti-IRF5, and anti-TGIF1.
    Article Snippet: Plasma from patients with SLE in 2 independent cohorts was screened for IgG and IgA seroreactivity against 1609 protein autoantigens using the i-Ome Discovery microarray (Sengenics), with 3 longitudinal assessments conducted in the smaller validation cohort.

    Article Title: T cell and autoantibody profiling for primary immune regulatory disorders.
    Article Snippet: Background: Limited clinical tools exist for characterizing primary immune regulatory disorders (PIRD).. Increased CD4CXCR5PD1 circulating T follicular helper (cTfh) cell percentages have been identified as a marker of active disease in some, but not all, autoimmune disorders.. Objective: To develop a diagnostic approach that combines measurements of cellular and serologic autoimmunity.

    Article Title: Advances in Extracellular Matrix-Associated Diagnostics and Therapeutics.
    Article Snippet: 2025, 14, 1856 31 of 50 biomarker discovery and introduced Sengenics’ revolutionary KREX® protein microarray technology.

    Article Title: New IgG and IgA autoantibody specificities against DNA-binding and RNA-binding proteins discriminate systemic lupus erythematosus from health and non-lupus autoimmunity-could anti-LIN28A enhance precision in diagnostics?
    Article Snippet: While most SLE autoantibody studies focus on the IgG isotype, including the 2 previous studies that used the Sengenics i-Ome microarray, our study also examined IgA autoantibodies.

    Article Title: Novel IgG and IgA autoantibodies validated in two independent cohorts are associated with disease activity and determine organ manifestations in systemic lupus erythematosus: implications for anti-LIN28A, anti-HMGN5, anti-IRF5, and anti-TGIF1.
    Article Snippet: Autoantibody measurement and gene expression analysis Plasma samples were screened for IgG and IgA autoantibody specificities against a panel of 1609 human proteins using the i-Ome Discovery protein microarray (Sengenics Corporation; Supplementary Material, sheet 1) [23].

    Article Title: New IgG and IgA autoantibody specificities against DNA-binding and RNA-binding proteins discriminate systemic lupus erythematosus from health and non-lupus autoimmunity-could anti-LIN28A enhance precision in diagnostics?
    Article Snippet: Two previous studies have used the Sengenics i-Ome highthroughput proteomic microarray to identify IgG autoantibodies in geographically distinct SLE populations from Singapore [25] and the UK [5].

    Article Title: Novel IgG and IgA autoantibodies validated in two independent cohorts are associated with disease activity and determine organ manifestations in systemic lupus erythematosus: implications for anti-LIN28A, anti-HMGN5, anti-IRF5, and anti-TGIF1.
    Article Snippet: To address this need, we aimed to uncover novel biomarkers that could enhance our ability to monitor SLE disease activity more accurately and tailor treatments more effectively using the i-Ome Discovery protein microarray (Sengenics Corporation) that encompasses 1609 protein autoantigens.

    Biomarker Discovery:

    Article Title: Poster Presentations
    Article Snippet: International Journal of Rheumatic Diseases, 2025 around 43% of patients develop Raynaud's phenomenon (RP).. Its presentation may be confused with some autoimmune diseases, including lupus and therefore should be considered in the differential of patients with secondary RP.. Case Study: A previously well, white male in his twenties, was diagnosed with retinal vasculopathy following a routine eye check.

    Article Title: Novel IgG and IgA autoantibodies validated in two independent cohorts are associated with disease activity and determine organ manifestations in systemic lupus erythematosus: implications for anti-LIN28A, anti-HMGN5, anti-IRF5, and anti-TGIF1.
    Article Snippet: Plasma from patients with SLE in 2 independent cohorts was screened for IgG and IgA seroreactivity against 1609 protein autoantigens using the i-Ome Discovery microarray (Sengenics), with 3 longitudinal assessments conducted in the smaller validation cohort.

    Article Title: T cell and autoantibody profiling for primary immune regulatory disorders.
    Article Snippet: Background: Limited clinical tools exist for characterizing primary immune regulatory disorders (PIRD).. Increased CD4CXCR5PD1 circulating T follicular helper (cTfh) cell percentages have been identified as a marker of active disease in some, but not all, autoimmune disorders.. Objective: To develop a diagnostic approach that combines measurements of cellular and serologic autoimmunity.

    Article Title: Advances in Extracellular Matrix-Associated Diagnostics and Therapeutics.
    Article Snippet: 2025, 14, 1856 31 of 50 biomarker discovery and introduced Sengenics’ revolutionary KREX® protein microarray technology.

    Article Title: New IgG and IgA autoantibody specificities against DNA-binding and RNA-binding proteins discriminate systemic lupus erythematosus from health and non-lupus autoimmunity-could anti-LIN28A enhance precision in diagnostics?
    Article Snippet: While most SLE autoantibody studies focus on the IgG isotype, including the 2 previous studies that used the Sengenics i-Ome microarray, our study also examined IgA autoantibodies.

    Article Title: Novel IgG and IgA autoantibodies validated in two independent cohorts are associated with disease activity and determine organ manifestations in systemic lupus erythematosus: implications for anti-LIN28A, anti-HMGN5, anti-IRF5, and anti-TGIF1.
    Article Snippet: Autoantibody measurement and gene expression analysis Plasma samples were screened for IgG and IgA autoantibody specificities against a panel of 1609 human proteins using the i-Ome Discovery protein microarray (Sengenics Corporation; Supplementary Material, sheet 1) [23].

    Article Title: New IgG and IgA autoantibody specificities against DNA-binding and RNA-binding proteins discriminate systemic lupus erythematosus from health and non-lupus autoimmunity-could anti-LIN28A enhance precision in diagnostics?
    Article Snippet: Two previous studies have used the Sengenics i-Ome highthroughput proteomic microarray to identify IgG autoantibodies in geographically distinct SLE populations from Singapore [25] and the UK [5].

    Article Title: Novel IgG and IgA autoantibodies validated in two independent cohorts are associated with disease activity and determine organ manifestations in systemic lupus erythematosus: implications for anti-LIN28A, anti-HMGN5, anti-IRF5, and anti-TGIF1.
    Article Snippet: To address this need, we aimed to uncover novel biomarkers that could enhance our ability to monitor SLE disease activity more accurately and tailor treatments more effectively using the i-Ome Discovery protein microarray (Sengenics Corporation) that encompasses 1609 protein autoantigens.

    Gene Expression:

    Article Title: Poster Presentations
    Article Snippet: International Journal of Rheumatic Diseases, 2025 around 43% of patients develop Raynaud's phenomenon (RP).. Its presentation may be confused with some autoimmune diseases, including lupus and therefore should be considered in the differential of patients with secondary RP.. Case Study: A previously well, white male in his twenties, was diagnosed with retinal vasculopathy following a routine eye check.

    Article Title: Novel IgG and IgA autoantibodies validated in two independent cohorts are associated with disease activity and determine organ manifestations in systemic lupus erythematosus: implications for anti-LIN28A, anti-HMGN5, anti-IRF5, and anti-TGIF1.
    Article Snippet: Plasma from patients with SLE in 2 independent cohorts was screened for IgG and IgA seroreactivity against 1609 protein autoantigens using the i-Ome Discovery microarray (Sengenics), with 3 longitudinal assessments conducted in the smaller validation cohort.

    Article Title: T cell and autoantibody profiling for primary immune regulatory disorders.
    Article Snippet: Background: Limited clinical tools exist for characterizing primary immune regulatory disorders (PIRD).. Increased CD4CXCR5PD1 circulating T follicular helper (cTfh) cell percentages have been identified as a marker of active disease in some, but not all, autoimmune disorders.. Objective: To develop a diagnostic approach that combines measurements of cellular and serologic autoimmunity.

    Article Title: Advances in Extracellular Matrix-Associated Diagnostics and Therapeutics.
    Article Snippet: 2025, 14, 1856 31 of 50 biomarker discovery and introduced Sengenics’ revolutionary KREX® protein microarray technology.

    Article Title: New IgG and IgA autoantibody specificities against DNA-binding and RNA-binding proteins discriminate systemic lupus erythematosus from health and non-lupus autoimmunity-could anti-LIN28A enhance precision in diagnostics?
    Article Snippet: While most SLE autoantibody studies focus on the IgG isotype, including the 2 previous studies that used the Sengenics i-Ome microarray, our study also examined IgA autoantibodies.

    Article Title: Novel IgG and IgA autoantibodies validated in two independent cohorts are associated with disease activity and determine organ manifestations in systemic lupus erythematosus: implications for anti-LIN28A, anti-HMGN5, anti-IRF5, and anti-TGIF1.
    Article Snippet: Autoantibody measurement and gene expression analysis Plasma samples were screened for IgG and IgA autoantibody specificities against a panel of 1609 human proteins using the i-Ome Discovery protein microarray (Sengenics Corporation; Supplementary Material, sheet 1) [23].

    Article Title: New IgG and IgA autoantibody specificities against DNA-binding and RNA-binding proteins discriminate systemic lupus erythematosus from health and non-lupus autoimmunity-could anti-LIN28A enhance precision in diagnostics?
    Article Snippet: Two previous studies have used the Sengenics i-Ome highthroughput proteomic microarray to identify IgG autoantibodies in geographically distinct SLE populations from Singapore [25] and the UK [5].

    Article Title: Novel IgG and IgA autoantibodies validated in two independent cohorts are associated with disease activity and determine organ manifestations in systemic lupus erythematosus: implications for anti-LIN28A, anti-HMGN5, anti-IRF5, and anti-TGIF1.
    Article Snippet: To address this need, we aimed to uncover novel biomarkers that could enhance our ability to monitor SLE disease activity more accurately and tailor treatments more effectively using the i-Ome Discovery protein microarray (Sengenics Corporation) that encompasses 1609 protein autoantigens.

    Activity Assay:

    Article Title: Poster Presentations
    Article Snippet: International Journal of Rheumatic Diseases, 2025 around 43% of patients develop Raynaud's phenomenon (RP).. Its presentation may be confused with some autoimmune diseases, including lupus and therefore should be considered in the differential of patients with secondary RP.. Case Study: A previously well, white male in his twenties, was diagnosed with retinal vasculopathy following a routine eye check.

    Article Title: Novel IgG and IgA autoantibodies validated in two independent cohorts are associated with disease activity and determine organ manifestations in systemic lupus erythematosus: implications for anti-LIN28A, anti-HMGN5, anti-IRF5, and anti-TGIF1.
    Article Snippet: Plasma from patients with SLE in 2 independent cohorts was screened for IgG and IgA seroreactivity against 1609 protein autoantigens using the i-Ome Discovery microarray (Sengenics), with 3 longitudinal assessments conducted in the smaller validation cohort.

    Article Title: T cell and autoantibody profiling for primary immune regulatory disorders.
    Article Snippet: Background: Limited clinical tools exist for characterizing primary immune regulatory disorders (PIRD).. Increased CD4CXCR5PD1 circulating T follicular helper (cTfh) cell percentages have been identified as a marker of active disease in some, but not all, autoimmune disorders.. Objective: To develop a diagnostic approach that combines measurements of cellular and serologic autoimmunity.

    Article Title: Advances in Extracellular Matrix-Associated Diagnostics and Therapeutics.
    Article Snippet: 2025, 14, 1856 31 of 50 biomarker discovery and introduced Sengenics’ revolutionary KREX® protein microarray technology.

    Article Title: New IgG and IgA autoantibody specificities against DNA-binding and RNA-binding proteins discriminate systemic lupus erythematosus from health and non-lupus autoimmunity-could anti-LIN28A enhance precision in diagnostics?
    Article Snippet: While most SLE autoantibody studies focus on the IgG isotype, including the 2 previous studies that used the Sengenics i-Ome microarray, our study also examined IgA autoantibodies.

    Article Title: Novel IgG and IgA autoantibodies validated in two independent cohorts are associated with disease activity and determine organ manifestations in systemic lupus erythematosus: implications for anti-LIN28A, anti-HMGN5, anti-IRF5, and anti-TGIF1.
    Article Snippet: Autoantibody measurement and gene expression analysis Plasma samples were screened for IgG and IgA autoantibody specificities against a panel of 1609 human proteins using the i-Ome Discovery protein microarray (Sengenics Corporation; Supplementary Material, sheet 1) [23].

    Article Title: New IgG and IgA autoantibody specificities against DNA-binding and RNA-binding proteins discriminate systemic lupus erythematosus from health and non-lupus autoimmunity-could anti-LIN28A enhance precision in diagnostics?
    Article Snippet: Two previous studies have used the Sengenics i-Ome highthroughput proteomic microarray to identify IgG autoantibodies in geographically distinct SLE populations from Singapore [25] and the UK [5].

    Article Title: Novel IgG and IgA autoantibodies validated in two independent cohorts are associated with disease activity and determine organ manifestations in systemic lupus erythematosus: implications for anti-LIN28A, anti-HMGN5, anti-IRF5, and anti-TGIF1.
    Article Snippet: To address this need, we aimed to uncover novel biomarkers that could enhance our ability to monitor SLE disease activity more accurately and tailor treatments more effectively using the i-Ome Discovery protein microarray (Sengenics Corporation) that encompasses 1609 protein autoantigens.



    Similar Products

    cta protein array  (Sengenics Corporation Pte)
    90
    Sengenics Corporation Pte cta protein array
    Antigen reactivities identified with ovarian cancer cohort 1 using <t> Sengenics </t> <t> CTA protein </t> arrays. Ovarian cancer ASC probes ( n = 11, A–K) and selected matched sera ( n = 5) were screened using <t> Sengenics </t> <t> CTA protein </t> arrays.
    Cta Protein Array, supplied by Sengenics Corporation Pte, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cta+protein+array/cta+protein+array/pmc08538754-157-2-1
    Average 90 stars, based on 1 article reviews
    cta protein array - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    cancer-testis antigens (cta) protein array  (Sengenics Corporation Pte)
    90
    Sengenics Corporation Pte cancer-testis antigens (cta) protein array
    Antigen reactivities identified with ovarian cancer cohort 1 using <t> Sengenics </t> <t> CTA protein </t> arrays. Ovarian cancer ASC probes ( n = 11, A–K) and selected matched sera ( n = 5) were screened using <t> Sengenics </t> <t> CTA protein </t> arrays.
    Cancer Testis Antigens (Cta) Protein Array, supplied by Sengenics Corporation Pte, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cta+protein+array/cancer+testis+antigens++cta++protein+array/pmc08538754-154-51-56
    Average 90 stars, based on 1 article reviews
    cancer-testis antigens (cta) protein array - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Antigen reactivities identified with ovarian cancer cohort 1 using Sengenics CTA protein arrays. Ovarian cancer ASC probes ( n = 11, A–K) and selected matched sera ( n = 5) were screened using Sengenics CTA protein arrays.

    Journal: International Journal of Molecular Sciences

    Article Title: Identification of Tumor Antigens in Ovarian Cancers Using Local and Circulating Tumor-Specific Antibodies

    doi: 10.3390/ijms222011220

    Figure Lengend Snippet: Antigen reactivities identified with ovarian cancer cohort 1 using Sengenics CTA protein arrays. Ovarian cancer ASC probes ( n = 11, A–K) and selected matched sera ( n = 5) were screened using Sengenics CTA protein arrays.

    Article Snippet: The Sengenics CTA protein array included 256 cancer-testis and associated antigens and was used to screen ASC probes at a 1:2 dilution and serum at a 1:800 dilution.

    Techniques:

    Study design diagram. Ovarian cancer cohort 1 and selected healthy and benign controls were screened using the CDI HuProt TM array and the Sengenics CTA protein array, which led to the identification of 50 candidate antigens. A custom array was developed and used to screen ovarian cancer cohort 2, as well as healthy and benign controls.

    Journal: International Journal of Molecular Sciences

    Article Title: Identification of Tumor Antigens in Ovarian Cancers Using Local and Circulating Tumor-Specific Antibodies

    doi: 10.3390/ijms222011220

    Figure Lengend Snippet: Study design diagram. Ovarian cancer cohort 1 and selected healthy and benign controls were screened using the CDI HuProt TM array and the Sengenics CTA protein array, which led to the identification of 50 candidate antigens. A custom array was developed and used to screen ovarian cancer cohort 2, as well as healthy and benign controls.

    Article Snippet: The Sengenics CTA protein array included 256 cancer-testis and associated antigens and was used to screen ASC probes at a 1:2 dilution and serum at a 1:800 dilution.

    Techniques: Protein Array